238 related articles for article (PubMed ID: 21232659)
21. Multiple myeloma precursor disease.
Landgren O; Waxman AJ
JAMA; 2010 Dec; 304(21):2397-404. PubMed ID: 21119086
[TBL] [Abstract][Full Text] [Related]
22. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.
Grass S; Preuss KD; Ahlgrimm M; Fadle N; Regitz E; Pfoehler C; Murawski N; Pfreundschuh M
Lancet Oncol; 2009 Oct; 10(10):950-6. PubMed ID: 19767238
[TBL] [Abstract][Full Text] [Related]
23. A rare condition: IgE type monoclonal gammopathy of undetermined significance.
Caldini A; Balboni F; Parronchi P; Scoccianti S; Biagioli T; Terreni A; Morrocchi B; Brogi M; Berardi M; Graziani M
Clin Chem Lab Med; 2014 Aug; 52(8):e183-5. PubMed ID: 24791823
[No Abstract] [Full Text] [Related]
24. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
25.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
26. [Pathogenesis of multiple myeloma].
Rasche L; Weinhold N
Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
[TBL] [Abstract][Full Text] [Related]
27. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
28. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
30. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
Thiago LS; Perez-Andres M; Balanzategui A; Sarasquete ME; Paiva B; Jara-Acevedo M; Barcena P; Sanchez ML; Almeida J; González M; San Miguel JF; Garcia-Sanz R; Orfao A
Haematologica; 2014 Jan; 99(1):155-62. PubMed ID: 23872308
[TBL] [Abstract][Full Text] [Related]
31. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.
Landgren O; Kyle RA; Rajkumar SV
Clin Cancer Res; 2011 Mar; 17(6):1243-52. PubMed ID: 21411440
[TBL] [Abstract][Full Text] [Related]
32. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
[TBL] [Abstract][Full Text] [Related]
33. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
34. A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma.
Vallet S; Hoyle NR; Kyle RA; Podar K; Pecherstorfer M
Leuk Lymphoma; 2018 Oct; 59(10):2431-2438. PubMed ID: 29345175
[TBL] [Abstract][Full Text] [Related]
35. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma.
Ludwig C; Williams DS; Bartlett DB; Essex SJ; McNee G; Allwood JW; Jewell E; Barkhuisen A; Parry H; Anandram S; Nicolson P; Gardener C; Seymour F; Basu S; Dunn WB; Moss PA; Pratt G; Tennant DA
Blood Cancer J; 2015 Oct; 5(10):e359. PubMed ID: 26473531
[No Abstract] [Full Text] [Related]
36. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
38. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
39. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.
Schmitz MF; Otten HG; Franssen LE; van Dorp S; Strooisma T; Lokhorst HM; van de Donk NW
Haematologica; 2014 Dec; 99(12):1846-53. PubMed ID: 25193963
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
